Table 2.
Association of CD33 SNPs with clinical endpoints in white AML patients treated on COG AAML30P1 and St Jude AML02 trials.
| CD33 SNP | COG-AAML03P1(with GO+ADE) | St Jude AML02 (without GO treatment) | ||
|---|---|---|---|---|
|
|
|
|||
| rs 35112940 (Arg304Gly) | 3 yr OS from end of course 1 | 3 yr OS from end of course 1 | ||
|
|
|
|||
| AA (n=6) | 50 ± 41 | AA (n=5) | 100 ± 0 | |
|
|
|
|||
| AG (n=34) | 71 ± 16 | AG (n=34) | 64.8 ± 8.6 | |
|
|
|
|||
| GG (n=101) | 84 ± 8 | GG (n=81) | 77.7 ± 4.9 | |
|
|
|
|||
| AA vs. AG vs. GG; p=0.036 | AA vs. AG vs. GG; p=0.23 | |||
| AA+AG vs. GG; p=0.018 | AA+AG vs. GG; p=0.61 | |||
|
|
|
|||
| rs 35112940 (Arg304Gly) | 3 yr DFS from end of course 1 | 3 yr DFS from end of course 1 | ||
|
|
|
|||
| AA (n=6) | 33 ± 39 | AA (n=5) | 80 ± 16 | |
|
|
|
|||
| AG (n=34) | 56 ± 17 | AG (n=29) | 67.6 ± 9.3 | |
|
|
|
|||
| GG (n=101) | 70 ± 9 | GG (n=59) | 79.3 ± 5.8 | |
|
|
|
|||
| AA vs. AG vs. GG; p=0.064 | AA vs. AG vs. GG; p=0.50 | |||
| AA vs. AG+GG; p=0.05 | AA vs. AG+GG; p=0.76 | |||
|
|
|
|||
| rs 35112940 (Arg304Gly) | 3 yr RR from end of course 1 | 3 yr RR from end of course 1 | ||
|
|
|
|||
| AA (n=6) | 67 ± 38 | AA (n=5) | 20 ± 20 | |
|
|
|
|||
| AG (n=34) | 41 ± 17 | AG (n=29) | 25.3 ± 8.5 | |
|
|
|
|||
| GG (n=101) | 24 ± 9 | GG (n=59) | 15.7 ± 4.9 | |
|
|
|
|||
| AA vs. AG vs. GG; p=0.018 | AA vs. AG vs. GG; p=0.55 | |||
| AA vs. AG+GG; p=0.021 | AA vs. AG+GG; p = 0.93 | |||
| AA+AG vs. GG; p=0.025 | AA+AG vs. GG; p = 0.29 | |||
|
|
|
|||
| rs180234 (3′UTR) | 3 yr TRM from end of course 1 | 3 yr TRM from end of course 1 | ||
|
|
|
|||
| CC (n=3) | 0 ± 0 | CC (n=4) | 0 ± 0 | |
|
|
|
|||
| CG (n=29) | 14 ± 13 | CG (n=12) | 8.3 ± 8.4 | |
|
|
|
|||
| GG (n=109) | 3 ± 3 | GG (n=73) | 9.9± 3.6 | |
|
|
|
|||
| CC vs. CG vs. GG; p=0.051 | CC vs. CG vs. GG; p=0.81 | |||
| CC+CG vs. GG; p=0.029 | CC+CG vs. GG; P=0.67 |